8:50
IMAPAC Opening Remarks
8:55
Chairman Opening Remarks
Opening Plenary: Building Southeast Asia’s Biologics & Vaccine Ecosystem
9:00
Panel Discussion: Building a Resilient Biologics & Vaccine Ecosystem in Southeast Asia: From Capacity to Capability
- Bridging gaps across R&D, manufacturing, and supply chain to create a connected regional ecosystem
- Public-private partnerships: Aligning governments, industry, and academia to accelerate innovation
- Strengthening regional self-sufficiency vs. global dependency in vaccine and biologics production
- Talent, infrastructure, and policy: What’s needed to position Southeast Asia as a global hub
Panelist:
👤 Dr. Mohd Azlan bin Zaharudin, Director, Malaysian Vaccine Project Office (MVPO), Ministry of Science, Technology & Innovation (MOSTI), Malaysia
👤 Dr. Soleh Ayubi, Chief of Country Representative, PATH, Indonesia
9:45
Enabling Southeast Asia's Vaccine & Biopharma Ecosystem Through Strategic Partnerships and Innovation
- Supporting vaccine and biologics development through integrated technology, manufacturing, and supply chain solutions
- Accelerating regional growth through public-private partnerships and ecosystem collaboration
- Building resilient and future-ready capabilities to strengthen Southeast Asia's position in the global life sciences industry
👤 Reserved for Solution Providers
10:00
Scaling for Resilience: Strengthening Local Manufacturing & Supply Chain Capabilities
- Investing in local manufacturing capacity vs. reliance on global supply chains
- Technology transfer models and partnerships with global biopharma players
- Workforce development: building a skilled talent pipeline for biologics production
- Ensuring quality, compliance, and regulatory readiness for global markets
👤 Dr. Heba Wali, Vice CEO, VBC Vaccines and Biotechnology City, Egypt
10:25
From Policy to Practice: Strengthening National Immunisation Ecosystems Across Southeast Asia
- Bridging policy and execution: overcoming gaps in last-mile vaccine delivery and coverage
- Strengthening public health infrastructure to support adult and life-course immunisation
- Integrating digital health systems for real-time monitoring, tracking, and decision-making
- Building resilient immunisation programmes in the face of future pandemics and outbreaks
👤 Vinod Kumar Bura, Coordinator IVD Unit, WHO SEARO ,India
10:50
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Next-Generation Vaccine Discovery & Platform Technologies
11:20
From Rational Design to AI/Automation‑Driven xRNA Platform and Product Development
- What are the advantages of the RNA modality in infectious disease development and broader therapeutic areas?
- How can we achieve deep optimization of RNA technologies?
- In which potential areas might RNA technology outperform other modalities?
👤 Dr. Wenshuo Zhou, Senior Director R&D & CEO Scientific Assistant, Abogen Biosciences, China
11:45
Platform Technologies for Speed & Scale: Enabling Rapid Vaccine Development
- Modular and plug-and-play platforms for rapid vaccine production
- Advances in lipid nanoparticles (LNPs) and delivery systems
- Standardization and scalability across different vaccine types
- Enabling tech transfer and global manufacturing readiness
👤 Reserved for Solution Providers
12:00
Financing the Future: Global South-Led Funding Mechanisms for Next-Generation Vaccine Innovation
- Funding gaps limiting vaccine discovery and platform technology development
- Sustainable financing models to accelerate innovation in emerging markets
- Public-private partnerships and regional investment mechanisms
- Building long-term R&D capacity and manufacturing readiness in the Global South
👤 Dr.Sushant Sahastrabuddhe, Deputy Director General, International Vaccine Institute (IVI), South Korea
12:25
Lunch, Exhibition Viewing & 1-1 Attendees Networking
Clinical Trials & Regulatory Harmonization in SEA
1:25
Speed vs. Compliance: Balancing Agility and Regulatory Rigor in Clinical Development
- Maintaining data integrity while accelerating trial timelines
- Risk-based approaches to regulatory review and monitoring
- Adaptive trial designs and their regulatory acceptance in Asia
- Managing variability in country-specific regulatory expectations
1:50
Decentralized & Hybrid Trials in SEA: Unlocking Patient Access Through Innovative Trial Models
- Enabling decentralized trials through telemedicine, eConsent, and remote monitoring tools
- Addressing regulatory acceptance of DCT models across SEA markets
- Expanding patient recruitment in rural and underserved populations
- Technology infrastructure and compliance considerations for hybrid trials
👤 Reserved for Solution Providers
2:05
Panel Discussion: From Fragmentation to Alignment: Accelerating Multi-Country Vaccine Trials in SEA
- Identify key bottlenecks in conducting simultaneous trials across multiple SEA countries.
- Examine harmonization of trial protocols, endpoints, and data standards.
- Discuss regulatory reliance models and mutual recognition agreements.
- Explore the role of CROs and regional trial networks in enabling scalability.
Panelist:
👤 Indriana Permatasari, Project Manager, International Vaccine Institute (IVI), Indonesia
2:45
Data Without Borders: Harmonizing Clinical Data Standards and Digital Integration
- Challenges in data standardization and interoperability across SEA
- Adoption of global standards (e.g., CDISC, eCTD)
- Cross-border data sharing, privacy regulations, and cybersecurity
- Role of digital platforms and decentralized trials
3:10
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Scaling Biomanufacturing Capacity & Technology Transfer Across SEA
3:40
Panel Discussion: Building LMIC Manufacturing Readiness: Scaling Vaccine Capacity Across Southeast Asia
- What infrastructure, talent, quality systems, and regulatory foundations are needed for sustainable vaccine production?
- How can stakeholders design scalable technology transfer models that build long-term local capability?
- What investments in training, GMP culture, and operational excellence are critical for successful scale-up?
- How can regional collaboration and partnerships strengthen supply chains and reduce import dependence?
4:25
Winning the race to the market: The blueprint for flawless tech transfer
- Technical complexity and knowhow
- Hard and soft infrastructure
- Operational challenges
- Regulatory bottlenecks
👤 Badarulhisam Abdul Rahman, PhD, Chief Scientific Officer, Pharmaniaga Berhad, Malaysia
4:50
Strengthening GMP and Quality Systems for Consistent Vaccine Output
- Building robust quality management systems in emerging manufacturing sites
- Harmonizing GMP standards across ASEAN markets
- Overcoming inspection readiness and compliance challenges
- Embedding quality-by-design (QbD) principles in vaccine production
5:15
Digitalizing Vaccine Manufacturing: Enabling Scale, Quality, and Real-Time Decision Making
- Leveraging digital twins, AI, and process analytics in biomanufacturing
- Real-time monitoring and predictive quality control systems
- Data integrity and integration across multi-site manufacturing networks
- How digitalization accelerates scale-up and tech transfer efficiency
5:40
Chairman Closing Remarks
5:50
End of Conference - Day 1
8:50
IMAPAC Opening Remarks
8:55
Chairman Opening Remarks
mRNA, Viral Vector & Novel Platforms for Fast-Response Vaccines
9:00
mRNA Portfolios After COVID: From Breakthrough Breakthroughs to Sustainable Vaccine Platforms
- How mRNA developers are transitioning from emergency-use success to scalable, multi-indication vaccine pipelines
- Advancing mRNA applications across infectious diseases, oncology, and personalized vaccines
- Comparing strengths, limitations, and hybrid strategies for rapid-response vaccine development
- Building resilient, cost-effective mRNA production and supply chains for global deployment
9:25
Monolith-Enabled RNA–LNP Manufacturing: High Yield, Consistent Quality, Faster Response
- Accelerating RNA–LNP production for rapid outbreak and pandemic response
- Improving RNA recovery and minimizing material loss vs. conventional methods
- Ensuring tight particle size, encapsulation efficiency, and batch consistency
- Enabling real-time analytics for faster release and GMP-ready manufacturing
👤 Reserved for Solution Providers
9:40
Establishment of an integrated, scalable workflow for high yield mRNA-LNP platform for vaccine development
- End to End mRNA Production Workflow Development
- Lipid Nanoparticle Formulation and Encapsulation Efficiency
- Scalability and Manufacturing Integration
- Platform Performance for Vaccine Applications
👤 Dr. Uma Nath Tripathi, Associate General Manager, Kashiv Biosciences LLC, India
10:05
Panel Discussion: Fast-Response Vaccines: Are Platform Technologies Ready for the Next Pandemic?
- Comparing speed, scalability, and flexibility of mRNA vs viral vectors
- Key bottlenecks in rapid design-to-deployment timelines
- Lessons from COVID-19: what worked, what didn’t
- Building platform readiness for future outbreak scenarios
10:35
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Vaccine Showcase: Emerging & Re-Emerging Infectious Diseases in South East Asia
11:05
RSV Prevention in Infants: Translating Clinical Evidence into Population-Level Protection
- Latest clinical and real-world evidence on RSV disease burden and vaccine effectiveness in infants and young children
- Understanding the impact of RSV prevention on hospitalizations, healthcare utilization, and long-term pediatric outcomes
- Identifying high-risk populations and strategies to maximize protection during the first years of life
- Translating evidence into national immunization policies and sustainable pediatric vaccination programs
👤 Senior Representative, Sanofi
11:30
AI-Powered Target Discovery for Next-Generation Polio Vaccines in Southeast Asia
- Using AI and genomic surveillance to identify targets and track cVDPVs across SEA
- Integrating regional data and sequencing networks for faster validation and outbreak prediction
- Accelerating vaccine design through machine learning and in silico modeling
- Translating AI insights into scalable development and equitable access in LMICs
👤 Reserved for Solution Providers
11:45
Advancing Inactivated Rotavirus Vaccines in SEA: From Microneedles to Market
- SEA Disease Burden: Addressing strain diversity and unmet vaccination needs
- Microneedle Innovation: Improving stability, delivery, and coverage in low-resource settings
- Scalable Manufacturing: Enabling cost-effective production and regional supply
- Access & Adoption: Aligning regulatory pathways and national immunization uptake
12:10
Lunch, Exhibition Viewing & 1-1 Attendees Networking
Vaccine Distribution & Cold Chain
1:10
Panel Discussion: Rethinking Vaccine Supply Chains for Sustainable, Localized Immunization in SEA
- Transitioning from donor-supported to locally financed immunization supply chains
- Strengthening national ownership across procurement, warehousing, and distribution
- Embedding resilience into supply chains for routine and pandemic preparedness
- Aligning policy, financing, and infrastructure for long-term sustainability
1:50
Beyond Approval: Scaling Awareness, Access, and Sustainable Uptake of New Vaccines
- Improving public awareness and vaccine confidence
- Expanding access through innovative funding and reimbursement models
- Addressing affordability and health equity challenges
- Strengthening stakeholder collaboration to drive adoption
- Ensuring long-term sustainability of vaccination programs
👤 Senior Representative, Sanofi
2:15
Reducing Vaccine Wastage: Inventory Management and Demand Forecasting in Cold Chain Systems
- Improving demand planning and stock allocation accuracy
- First-expiry-first-out (FEFO) and inventory tracking systems
- Minimizing overstocking and stockouts across regions
- Role of analytics and AI in supply chain optimization
👤 Dr. Soleh Ayubi, Chief of Country Representative, PATH, Indonesia
2:40
Fireside Chat: Needle-Free, Not Market-Free — Unlocking Next-Gen Vaccine Delivery
- Scaling Innovation: Driving adoption through PPPs, tech transfer, and localized manufacturing
- System Readiness: Overcoming infrastructure, regulatory, and program integration barriers
- Formulation Focus: Advancing adjuvants and thermostable platforms for scalable delivery
- Strategic Alignment: Coordinating R&D, policy, and supply chain for real-world deployment
3:05
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Leadership Panel: Can Southeast Asia Become a Global Biomanufacturing Powerhouse?
3:40
Leadership Panel: Can Southeast Asia Become a Global Vaccine & Biomanufacturing Powerhouse?
- What will it take for Southeast Asia to become a leading hub for vaccine and biologics manufacturing?
- How can governments and industry accelerate investments in talent, infrastructure, and advanced manufacturing capabilities?
- What role can regional collaboration play in strengthening supply chain resilience and reducing reliance on imports?
Panelist
👤 Dr. Neni Nurainy, Head of Translational Development of Life Science Product, Bio Farma, Indonesia
4:20
Strengthening GMP and Quality Systems Across Emerging Manufacturing Sites
- Building robust quality culture and compliance systems
- Digital QA/QC and data integrity practices
- Inspection readiness for US FDA, EMA, and WHO PQ
- Managing deviations and ensuring batch consistency
👤 Vipul Doshi, Chief Quality and Compliance Officer, Zydus Lifesciences, India
4:45
Leadership Panel: Building a Self-Reliant Life Sciences Ecosystem in Southeast Asia: From Innovation to Commercialization
- How can Southeast Asia strengthen its end-to-end ecosystem across R&D, clinical development, manufacturing, and commercialization?
- What partnerships are needed between governments, academia, investors, and industry to accelerate innovation?
- How can the region attract global investment while improving access to vaccines and biologics for local populations?
5:25
Chairman Closing Remarks
5:30
End of Conference
For Speaking Opportunities, Kindly Contact:
Lara Santiago
Senior Portfolio Specialist
[email protected] | +63 91762 10686
